Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
All Genders
NCT06880835

Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery

Led by Jaeb Center for Health Research · Updated on 2025-09-23

30

Participants Needed

3

Research Sites

51 weeks

Total Duration

On this page

Sponsors

J

Jaeb Center for Health Research

Lead Sponsor

M

Mannkind Corporation

Collaborating Sponsor

AI-Summary

What this Trial Is About

This investigator-initiated study will enroll about 30 adults 18 to 65 years of age with type 1 diabetes (T1D) who are using the Tandem t:slim X2 insulin pump or Tandem Mobi insulin pump with Control-IQ or Control-IQ+ technology ("Control-IQ" which will refer to either Control-IQ or Control-IQ+). The study is being done to find out if inhaled insulin given for a meal is safer and better to use than a bolus of insulin through your pump when you exercise following a meal. Participants are asked to complete three study exercise visits in the clinic.

CONDITIONS

Official Title

Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Able to provide informed consent
  • Age 18 to 65 years
  • Clinical diagnosis of type 1 diabetes
  • Using Tandem t:slim X2 or Tandem Mobi insulin pump with Control-IQ for at least 90 days before screening
  • Using insulin aspart or insulin lispro in the insulin pump
  • Total daily insulin dose between 20 and 80 units
  • Usual rapid acting analogue insulin bolus for a 50 gram carbohydrate lunch meal is 12 units or less
  • Physically active with at least three moderate or vigorous exercise sessions of 30 minutes each per week
  • No medical, psychiatric, or other conditions or medications that pose safety concerns for study participation
  • No electrocardiogram abnormalities increasing exercise risk, as judged by the investigator
  • Investigator believes participant can safely follow the study protocol
  • Able to read and understand written and spoken English or Spanish
Not Eligible

You will not qualify if you...

  • Use of inhaled insulin within one week before screening
  • History of asthma, COPD, or other significant lung or cardiopulmonary diseases
  • Smoking (cigarettes, cigars, pipes, marijuana, vaping) within 90 days before screening or plans to smoke during the study
  • History or current diagnosis of lung cancer
  • Forced expiratory volume in 1 second (FEV1) less than 70% of predicted value
  • Pregnant, lactating, planning pregnancy, or childbearing potential without acceptable birth control
  • Severe hypoglycemia event within 90 days before screening
  • Diabetic ketoacidosis episode within 90 days before screening
  • Any disease or medication (e.g., beta blockers) impacting glucose metabolism
  • Use of non-insulin glucose-lowering or weight-reduction medication with glucose effect within 4 weeks before screening
  • Exposure to investigational drugs within 90 days before screening
  • Current or planned acute use of oral, inhaled, or injectable glucocorticoids (topical or intranasal allowed)
  • Current use of Hydroxyurea medication
  • Current or planned low carbohydrate diet (<50 grams/day) or low calorie diet (<800 kcal/day)
  • Current treatment for diabetic retinopathy
  • Known stage 4 or 5 chronic kidney disease or on dialysis
  • Having a direct supervisor or first-degree relative involved in the clinical trial conduct

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

University of Louisville

Louisville, Kentucky, United States, 40202

Actively Recruiting

2

University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

3

University of Washington

Seattle, Washington, United States, 98195

Actively Recruiting

Loading map...

Research Team

R

Robin Gal, MSPH

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here